BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) by Bristol Myers Squibb is programmed death receptor-1-directed antibody interactions [moa]. First approved in 2024.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDIVO QVANTIG is a subcutaneous formulation combining nivolumab (a PD-1 checkpoint inhibitor) with hyaluronidase to enable rapid subcutaneous delivery of an established immunotherapy. It represents a patient-convenience innovation for oncology patients by replacing intravenous administration with subcutaneous injection. The hyaluronidase enzyme facilitates subcutaneous tissue permeability, allowing larger antibody doses to be delivered via needle injection.
Growth
Early-stage growth asset with moderate competitive pressure (30/100); commercial teams will focus on market penetration and formulary access strategies for this newly approved convenience formulation.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig
Started Aug 2025
200 enrolled
Cancer
Career Relevance
This newly approved product offers near-term growth career opportunities in brand management, field sales, and market access as Bristol Myers Squibb drives formulary coverage and physician/patient adoption of the subcutaneous formulation. Roles will emphasize competitive differentiation on convenience, patient outcomes, and payer value propositions in a crowded checkpoint inhibitor landscape.
Brand Manager
Worked on OPDIVO QVANTIG at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.